Inactivation patterns of NF2 and DAL-1/4.1B (EPB41L3) in sporadic meningioma
- PMID: 16213361
- DOI: 10.1016/j.cancergencyto.2005.04.003
Inactivation patterns of NF2 and DAL-1/4.1B (EPB41L3) in sporadic meningioma
Abstract
The molecular basis of tumorigenesis and tumor progression in meningiomas is not fully understood. The neurofibromatosis 2 (NF2) locus is inactivated in 50-60% of sporadic meningiomas, but the genetic basis of sporadic meningiomas not inactivated at the NF2 locus remains unclear. Specifically, there is conflicting data regarding the role of the tumor suppressor gene DAL-1/4.1B. Using microsatellite markers, we studied 63 sporadic meningiomas to determine loss of heterozygosity (LOH) at the NF2 and DAL-1/4.1B loci. Array comparative genomic hybridization analysis of 52 of these tumors was performed to determine copy number changes on chromosomes 18 and 22. Forty-one of 62 informative tumors showed LOH at the NF2 locus (66%) while only 12 of 62 informative tumors (19%) showed LOH of DAL-1/4.1B. Eleven of 12 (92%) tumors with DAL-1/4.1B LOH also had NF2 LOH. Monosomy or large deletions of chromosomes 18 and 22 were the main mechanism for LOH in these tumors. These studies implicate the DAL-1/4.1B locus in sporadic meningiomas less commonly than reported previously, and suggest that it is a progression rather than an initiation locus. Furthermore, we found the majority of meningiomas developed monosomy rather than isodisomy at the NF2 and DAL-1/4.1B loci as the mechanism for LOH.
Similar articles
-
Tight association of loss of merlin expression with loss of heterozygosity at chromosome 22q in sporadic meningiomas.Cancer Res. 1999 Dec 1;59(23):5995-8. Cancer Res. 1999. PMID: 10606247
-
Mutational analysis of the DAL-1/4.1B tumour-suppressor gene locus in meningiomas.Int J Mol Med. 2005 Oct;16(4):771-4. Int J Mol Med. 2005. PMID: 16142420
-
NF2 gene mutations and allelic status of 1p, 14q and 22q in sporadic meningiomas.Oncogene. 1999 Apr 1;18(13):2231-9. doi: 10.1038/sj.onc.1202531. Oncogene. 1999. PMID: 10327069
-
The neurofibromatosis 2 (NF2) tumour suppressor gene: implications beyond the hereditary tumour syndrome?Cancer Surv. 1995;25:207-18. Cancer Surv. 1995. PMID: 8718520 Review.
-
[A new tumor suppressor gene responsible for type 2 neurofibromatosis is inactivated in neurinoma and meningioma].Rev Neurol (Paris). 1996 Jan;152(1):1-10. Rev Neurol (Paris). 1996. PMID: 8729390 Review. French.
Cited by
-
Genomic sequencing of meningiomas identifies oncogenic SMO and AKT1 mutations.Nat Genet. 2013 Mar;45(3):285-9. doi: 10.1038/ng.2526. Epub 2013 Jan 20. Nat Genet. 2013. PMID: 23334667 Free PMC article.
-
Meningioma: A Review of Clinicopathological and Molecular Aspects.Front Oncol. 2020 Oct 23;10:579599. doi: 10.3389/fonc.2020.579599. eCollection 2020. Front Oncol. 2020. PMID: 33194703 Free PMC article. Review.
-
Erythrocyte membrane protein band 4.1-like 3 inhibits osteosarcoma cell invasion through regulation of Snai1-induced epithelial-to-mesenchymal transition.Aging (Albany NY). 2020 Dec 11;13(2):1947-1961. doi: 10.18632/aging.202158. Epub 2020 Dec 11. Aging (Albany NY). 2020. PMID: 33323539 Free PMC article.
-
A role for the p53 pathway in the pathology of meningiomas with NF2 loss.J Neurooncol. 2009 Feb;91(3):265-70. doi: 10.1007/s11060-008-9721-3. Epub 2008 Nov 1. J Neurooncol. 2009. PMID: 18974932 Free PMC article.
-
Gene expression profiles of meningiomas are associated with tumor cytogenetics and patient outcome.Brain Pathol. 2009 Jul;19(3):409-20. doi: 10.1111/j.1750-3639.2008.00191.x. Epub 2008 Jul 15. Brain Pathol. 2009. PMID: 18637901 Free PMC article.
Publication types
MeSH terms
Substances
Grants and funding
LinkOut - more resources
Full Text Sources
Research Materials
Miscellaneous